Latest News and Press Releases

Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitalization provides possible...

NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for...

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...

NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCPK: DCTH) has closed on its previously announced private placement with gross...

NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (OTCPK: DCTH) today announced that it has entered into a definitive agreement for...

NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...

NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...

NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...